{"id":78041,"date":"2026-01-15T09:50:54","date_gmt":"2026-01-15T08:50:54","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=78041"},"modified":"2026-01-15T09:50:57","modified_gmt":"2026-01-15T08:50:57","slug":"embl-alumni-in-action-norbert-kraut","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/","title":{"rendered":"EMBL alumni in action: Norbert Kraut"},"content":{"rendered":"\n

When EMBL alumnus Norbert Kraut walks into a cancer conference today, it\u2019s often with exciting updates for the cancer community.<\/p>\n\n\n\n

Kraut, now a senior executive scientist at Boehringer Ingelheim, has spent the last decade leading large international oncology research teams. One of their major achievements: a new HER2-targeted tyrosine kinase inhibitor for a rare form of non-small cell lung cancer (NSCLC), which is particularly aggressive in women and non-smokers. The drug recently received accelerated approval in the United States, China, and Japan.<\/p>\n\n\n\n

\u201cIt\u2019s one of my proudest moments in science,\u201d he said. \u201cTo see patients who were told they had only months to live, now back with their families, returning to work, even running half marathons again.\u201d<\/p>\n\n\n\n

Tackling a deadly cancer subtype<\/strong><\/h2>\n\n\n\n

Lung cancer remains the world\u2019s leading cause of cancer death. A small but important subset of NSCLC is driven by HER2 mutations \u2013 approximately 40,000 new diagnoses per year worldwide, often in people who have never smoked. These tumours tend to spread quickly, especially to the brain, and respond poorly to standard chemo- and immunotherapy.<\/p>\n\n\n\n

\u201cFor these patients, there were basically no effective targeted options,\u201d Kraut explained. \u201cThe medical need had not been addressed.\u201d<\/p>\n\n\n\n

Boehringer Ingelheim\u2019s teams set out to design a drug that would effectively target HER2 mutations that drive the cancer, spare closely related targets that cause undesired secondary effects, be administered orally, so patients could take the medicine at home, and work in patients with brain metastases.<\/p>\n\n\n\n

Over eight years, through what Kraut describes as \u2018a detective game in drug design\u2019, the team combined structural biology, medicinal chemistry, and sophisticated cancer models to create a molecule that fits the unusually tight HER2 binding pocket created by these mutations.<\/p>\n\n\n\n

From lab to patients \u2013 and a 70% response rate<\/strong><\/h2>\n\n\n\n

Clinical trials began in 2021, in the middle of the pandemic. Even in early stages, investigators reported that tumours were shrinking at low doses of the drug. The final study, published in the New England Journal of Medicine<\/em><\/a>, showed that in approximately 70% of patients with HER2-mutant NSCLC \u2013 many of whom had already received other therapies \u2013 tumours shrank significantly. Trial participants reported milder side effects than with many existing treatments, and the once-daily tablet meant fewer hospital visits.<\/p>\n\n\n\n

As oncologists have referred to the drug as a \u2018game changer\u2019 <\/a>for this patient group, trials are now exploring the drug for first-line therapy (earlier in the treatment course), adjuvant use directly after surgery to prevent or delay recurrence, and for other HER2-driven cancers beyond those found in the lung.<\/p>\n\n\n\n

The EMBL training that shaped an industry leader<\/strong><\/h2>\n\n\n\n

Kraut attributes the roots of his success to his days as a PhD student at EMBL Heidelberg in the 1990s. There, he worked with Thomas Graf on elucidating key molecular mechanisms of tumourigenesis. <\/p>\n\n\n\n

\u201cAt EMBL I learned a collaborative, collegial way of doing science,\u201d he recalled. \u201cThere was a lot of freedom, a very international environment, and constant networking. That spirit has stayed with me throughout my career.\u201d<\/p>\n\n\n\n

After a postdoc in Seattle, he joined Boehringer Ingelheim, where he became Global Head of Cancer Research, responsible for strategy, a research portfolio, and a large international team of scientists across geographies, as well as a broad range of biotech and academic partnerships. Under his leadership, the company has advanced multiple cancer drugs to patients, including therapies for other lung cancer subtypes and a range of solid cancers.<\/p>\n\n\n\n

Kraut also continued to build on the EMBL network. A long-term collaboration with fellow EMBL alumnus Giulio Draetta <\/strong>and his team at the MD Anderson Cancer Centre in Houston, for example, provided key translational models for precision oncology, including work that contributed to the HER2 inhibitor programme.<\/p>\n\n\n\n

\u201cMany of the critical ideas and technologies in our pipeline have roots in fundamental research,\u201d he said. \u201cInstitutes like EMBL and the Institute of Molecular Pathology in Vienna (where Kraut is on its Scientific Advisory Board) are driven by curiosity and create the concepts and tools we then translate into novel medicines.\u201d<\/p>\n\n\n\n

Driven by patients and scientific excellence<\/strong><\/h2>\n\n\n\n

Kraut\u2019s motivation is deeply personal. Early in his career, his postdoctoral mentor, Harold Weintraub, and later his mother, both died from aggressive brain tumours.<\/p>\n\n\n\n

\u201cThose experiences stayed with me,\u201d he said. \u201cFor the past 20 years, my main driver has been to make a real difference for cancer patients \u2013 to turn cutting-edge science into therapies that change the trajectory of their disease.\u201d<\/p>\n\n\n\n

That goal now extends beyond oncology. In his current role, Kraut works across therapeutic areas, from cancer and lung disease to cardiometabolic disorders, neuroscience, and emerging fields. There, he helps to identify and advance the most promising therapeutic concepts worldwide.<\/p>\n\n\n\n

EMBL alumni: seeding impact far beyond EMBL\u2019s walls<\/strong><\/h2>\n\n\n\n

Kraut is one of more than 11,000 EMBL alumni worldwide, many of whom now hold leadership roles in academia, industry, clinical research, and policy. Their work shapes how life sciences are conducted across Europe and beyond.<\/p>\n\n\n\n

\u201cI see EMBL as a blueprint for how to do collaborative, excellent science,\u201d he says. \u201cThe training and network I gained here have been crucial at every step \u2013 from my first industry jobs to leading global research teams and bringing new cancer drugs to patients.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.<\/p>\n","protected":false},"author":11,"featured_media":78085,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17593],"tags":[80,38,42,4760],"embl_taxonomy":[5794],"class_list":["post-78041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-people-perspectives","tag-alumni","tag-cancer","tag-genomics","tag-precision-medicine","embl_taxonomy-alumni-relations"],"acf":{"vfwp-news_embl_taxonomy":[5794],"featured":true,"show_featured_image":false,"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"article_intro":"

From early research days at EMBL to developing a novel cancer drug, an alumnus discusses his approach to hard-to-treat lung cancer<\/p>\n","related_links":false,"source_article":false,"in_this_article":false,"press_contact":"None","article_translations":false,"languages":""},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"bc1eaadd-1f50-4140-8e9b-e58fc33a39fc\";i:2;s:36:\"c07b3f46-3e45-495a-9902-ba71c4ffdd6d\";}","parents":[],"name":["Alumni Relations"],"slug":"alumni-relations","description":"What > About EMBL > Alumni Relations"}],"yoast_head":"\nEMBL alumni in action: Norbert Kraut | EMBL<\/title>\n<meta name=\"description\" content=\"Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMBL alumni in action: Norbert Kraut | EMBL\" \/>\n<meta property=\"og:description\" content=\"Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T08:50:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T08:50:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mehrnoosh Rayner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mehrnoosh Rayner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\"},\"author\":{\"name\":\"Mehrnoosh Rayner\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/444ed8e47e3d36971e06cf041be5fefb\"},\"headline\":\"EMBL alumni in action: Norbert Kraut\",\"datePublished\":\"2026-01-15T08:50:54+00:00\",\"dateModified\":\"2026-01-15T08:50:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\"},\"wordCount\":869,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png\",\"keywords\":[\"alumni\",\"cancer\",\"genomics\",\"precision medicine\"],\"articleSection\":[\"People & Perspectives\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\",\"url\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\",\"name\":\"EMBL alumni in action: Norbert Kraut | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png\",\"datePublished\":\"2026-01-15T08:50:54+00:00\",\"dateModified\":\"2026-01-15T08:50:57+00:00\",\"description\":\"Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png\",\"width\":1000,\"height\":600,\"caption\":\"An EMBL alumnus, Norbert Kraut has focused in on one of the hardest-to-treat lung cancers. Credit: Boehringer Ingelheim\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/444ed8e47e3d36971e06cf041be5fefb\",\"name\":\"Mehrnoosh Rayner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/19398b667ee5964cc64f755ede910f7f725edb8c65e42beceed53b12c313f628?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/19398b667ee5964cc64f755ede910f7f725edb8c65e42beceed53b12c313f628?s=96&d=mm&r=g\",\"caption\":\"Mehrnoosh Rayner\"},\"description\":\"Mehrnoosh Rayner is Head of Alumni Relations at EMBL. Her work in communications started at Edinburgh University 25 years ago and continues in support of the EMBL community today.\",\"url\":\"https:\/\/www.embl.org\/news\/author\/mehrnoosh-rayner\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EMBL alumni in action: Norbert Kraut | EMBL","description":"Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/","og_locale":"en_US","og_type":"article","og_title":"EMBL alumni in action: Norbert Kraut | EMBL","og_description":"Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.","og_url":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2026-01-15T08:50:54+00:00","article_modified_time":"2026-01-15T08:50:57+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","type":"image\/png"}],"author":"Mehrnoosh Rayner","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Mehrnoosh Rayner","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/"},"author":{"name":"Mehrnoosh Rayner","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/444ed8e47e3d36971e06cf041be5fefb"},"headline":"EMBL alumni in action: Norbert Kraut","datePublished":"2026-01-15T08:50:54+00:00","dateModified":"2026-01-15T08:50:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/"},"wordCount":869,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","keywords":["alumni","cancer","genomics","precision medicine"],"articleSection":["People & Perspectives"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/","url":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/","name":"EMBL alumni in action: Norbert Kraut | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","datePublished":"2026-01-15T08:50:54+00:00","dateModified":"2026-01-15T08:50:57+00:00","description":"Alumnus Norbert Kraut reflects on how his time at EMBL led to his successes in addressing hard-to-treat lung cancer.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/people-perspectives\/embl-alumni-in-action-norbert-kraut\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","width":1000,"height":600,"caption":"An EMBL alumnus, Norbert Kraut has focused in on one of the hardest-to-treat lung cancers. Credit: Boehringer Ingelheim"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/444ed8e47e3d36971e06cf041be5fefb","name":"Mehrnoosh Rayner","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/19398b667ee5964cc64f755ede910f7f725edb8c65e42beceed53b12c313f628?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/19398b667ee5964cc64f755ede910f7f725edb8c65e42beceed53b12c313f628?s=96&d=mm&r=g","caption":"Mehrnoosh Rayner"},"description":"Mehrnoosh Rayner is Head of Alumni Relations at EMBL. Her work in communications started at Edinburgh University 25 years ago and continues in support of the EMBL community today.","url":"https:\/\/www.embl.org\/news\/author\/mehrnoosh-rayner\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2026\/01\/Norbert-Kraut.png","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/78041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=78041"}],"version-history":[{"count":2,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/78041\/revisions"}],"predecessor-version":[{"id":78097,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/78041\/revisions\/78097"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/78085"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=78041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=78041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=78041"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=78041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}